Tachyon Collaborates with AbCellera to Develop Novel Antibody Therapies Targeting TGF-β Superfamily Member for Cancer
Shots:
- AbCellera to receive milestones and royalties on products that are derived from its Ab discovery platform. Additionally- AbCellera has the option to invest in pre/ clinical development in exchange for an increased share of product sales
- The collaboration will accelerate the translation of a novel research & cancer drug target into a first-in-class Ab therapeutics for patients with advanced cancers and limited treatment option
- LEFTY1 is a dual inhibitor of the NODAL/SMAD2 and BMP7/SMAD5 pathway that regulates cancer stem cell biology and unregulated tumor cell growth
to | Ref: Businesswire | Image: AbCellera
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com